Charter Pacific

Charter Pacific Corporation is an Australian-based investment company that has historically played a significant role in the commercialization of life science and technology assets. Founded in 1988, the firm gained prominence in the biotech sector through its major investment in ChemGenex Pharmaceuticals, which developed targeted medicines for cancer and metabolic diseases. The company was also involved in high-profile litigation and commercialization efforts regarding the Exelgram anti-counterfeiting technology and gene therapy patents licensed from CSIRO. While its current focus has shifted toward biometric security technologies, its legacy in the pharmaceutical industry remains defined by its strategic venture capital support for oncology and metabolic drug development programs.